PTSD psychotherapy is enhanced with D-cycloserine

(Press-News.org) Philadelphia, PA, June 4, 2012 – Posttraumatic stress disorder (PTSD) is among the most common, distressing, and disabling medical consequences of combat or other extremely stressful life events. The first-line treatment for PTSD is exposure therapy, a type of behavioral therapy where patients confront their fears in a safe environment. Although it is an effective treatment, many patients still experience symptoms after treatment and there is a relatively high drop-out rate.

In an effort to improve existing treatments, a new study appearing in Biological Psychiatry this week has tested a novel hypothesis about the treatment of PTSD derived from prior work in animal models and other anxiety disorders. They examined whether the impact of psychotherapy could be enhanced by administering D-cycloserine (DCS), a drug that does not directly treat the symptoms of PTSD, but rather promotes neuroplasticity, i.e., makes brain circuits better able to remodel themselves in the context of experience.

To test this, researchers recruited individuals with PTSD, all of whom received up to 10 weekly sessions of exposure therapy. They were randomized to receive doses of either DCS or placebo before each session, but did not know which they were receiving. The severity of their symptoms was assessed before and after treatment.

All patients experienced a reduction in symptoms due to the exposure therapy, regardless of whether they had received DCS augmentation or placebo. However, DCS did enhance the effects of exposure therapy in a specific subgroup of patients. Those who had more severe PTSD prior to treatment and needed longer treatment had a greater reduction in symptoms when they received DCS, compared to those who received placebo.

"Our study showed that some PTSD patients respond well and fast to exposure and for them, there seems no need to augment the therapy. In contrast, those patients with severe PTSD symptoms and who fail to respond to exposure sessions may benefit from augmentation with DCS," explained first author Dr. Rianne de Kleine. "It seems that DCS is beneficial for exactly those patients we aimed for: the more severe patients who do not respond to first-line treatment."

"This approach may have important implications for the treatment of PTSD. Two decades of brain research suggests that severe psychological stress causes atrophy of some of the fine connections in the brain and reductions in the volume of brain regions involved in emotion and memory. Thus, individuals with PTSD may have deficits in neuroplasticity that get in the way of effective treatment," commented Dr. John Krystal, Editor of Biological Psychiatry. "D-cycloserine may reduce this deficit in neuroplasticity and increase the response to psychotherapy, in this case a psychotherapy approach that involves exposing people to reminders and memories of the trauma."

The authors conclude that additional work is warranted to explore whether this combination can become an effective intervention to treat the symptoms of PTSD.

###The article is "A Randomized Placebo-Controlled Trial of D-Cycloserine to Enhance Exposure Therapy for Posttraumatic Stress Disorder" by Rianne A. de Kleine, Gert-Jan Hendriks, Wendy J.C. Kusters, Theo G. Broekman, and Agnes van Minnen (doi: 10.1016/j.biopsych.2012.02.033). The article appears in Biological Psychiatry, Volume 71, Issue 11 (June 1, 2012), published by Elsevier.

Notes for editors Full text of the article is available to credentialed journalists upon request; contact Rhiannon Bugno at +1 214 648 0880 or Biol.Psych@utsouthwestern.edu. Journalists wishing to interview the authors may contact Rianne de Kleine at +31 248200802 or r.de.kleine@propersona.nl.

The authors' affiliations, and disclosures of financial and conflicts of interests are available in the article.

John H. Krystal, M.D., is Chairman of the Department of Psychiatry at the Yale University School of Medicine and a research psychiatrist at the VA Connecticut Healthcare System. His disclosures of financial and conflicts of interests are available here.

About Biological Psychiatry Biological Psychiatry is the official journal of the Society of Biological Psychiatry, whose purpose is to promote excellence in scientific research and education in fields that investigate the nature, causes, mechanisms and treatments of disorders of thought, emotion, or behavior. In accord with this mission, this peer-reviewed, rapid-publication, international journal publishes both basic and clinical contributions from all disciplines and research areas relevant to the pathophysiology and treatment of major psychiatric disorders.

The journal publishes novel results of original research which represent an important new lead or significant impact on the field, particularly those addressing genetic and environmental risk factors, neural circuitry and neurochemistry, and important new therapeutic approaches. Reviews and commentaries that focus on topics of current research and interest are also encouraged.

Biological Psychiatry is one of the most selective and highly cited journals in the field of psychiatric neuroscience. It is ranked 4th out of 126 Psychiatry titles and 15th out of 237 Neurosciences titles in the Journal Citations Reports® published by Thomson Reuters. The 2010 Impact Factor score for Biological Psychiatry is 8.674.

About Elsevier Elsevier is a world-leading provider of scientific, technical and medical information products and services. The company works in partnership with the global science and health communities to publish more than 2,000 journals, including The Lancet and Cell, and close to 20,000 book titles, including major reference works from Mosby and Saunders. Elsevier's online solutions include SciVerse ScienceDirect, SciVerse Scopus, Reaxys, MD Consult and Mosby's Nursing Suite, which enhance the productivity of science and health professionals, and the SciVal suite and MEDai's Pinpoint Review, which help research and health care institutions deliver better outcomes more cost-effectively.

A global business headquartered in Amsterdam, Elsevier employs 7,000 people worldwide. The company is part of Reed Elsevier Group PLC, a world-leading publisher and information provider, which is jointly owned by Reed Elsevier PLC and Reed Elsevier NV. The ticker symbols are REN (Euronext Amsterdam), REL (London Stock Exchange), RUK and ENL (New York Stock Exchange).

Media contact Rhiannon Bugno
Editorial Office, Biological Psychiatry
+1 214 648 0880
biol.psych@utsouthwestern.edu